Answers are grounded in this paper and cite their sources.
No AccessJournal of Urology1 Mar 1981The Use of Intravesical Thio-Tepa in the Management of Non-invasive Carcinoma of the Bladder Warren W. Koontz, George R. Prout, Wade Smith, William J. Frable, and Janet E. Minnis Warren W. KoontzWarren W. Koontz More articles by this author , George R. ProutGeorge R. Prout More articles by this author , Wade SmithWade Smith More articles by this author , William J. FrableWilliam J. Frable More articles by this author , and Janet E. MinnisJanet E. Minnis More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(17)55018-1AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Two separate uses of intravesical therapy with thio-tepa were tested: 1) the ablative effect on noninvasive carcinoma of the bladder (that is treatment) and 2) the prophylactic effect in the prevention of new or recurrent tumors (that is prophylaxis). Of the 95 patients treated with thio-tepa for the ablation of incompletely resected carcinoma of the bladder (stages O and A) 45 (47 per cent) were free of disease after 2 treatment courses. The success rate was not affected by the dose (30 or 60mg.) or by pathologic assessment of stage and grade. The number of tumors was associated with response to treatment. Patients with 4 or more tumors did not do as well as patients with less than 4 (success rates of 36 and 62 per cent, respectively, which is significant statistically, p equals 0.02). The prophylaxis study included 93 patients: 23 on 30mg. dose, 23 on 60mg. and 47 controls. The interval free of disease was longer for patients receiving thio-tepa prophylaxis compared to the controls (statistically significant difference). The results with the 30 and 60mg. regimens were similar. The interval free of disease in the prophylaxis group appeared to be influenced by the presence or absence of cancer cells in the cytology specimens obtained before randomization. Although the difference was not statistically significant for these patients the time to disease recurrence was longer for the patients with negative cytology reports compared to patients with positive (cancer cells present) cytology reports. Patients who had been treated successfully with thio-tepa for incompletely resected tumor did well on the prophylaxis regimen (100 per cent were free of disease at 12 months). Of particular interest is the relatively favorable interval free of disease for patients who were treated successfully with thio-tepa for ablation of incompletely resected tumor but did not receive thio-tepa prophylaxis (that is randomized to the control group). In this group 60 per cent of the patients were free of disease at 12 months. © 1981 by The American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetailsCited byGofrit O, Zorn K, Shikanov S and Steinberg G (2018) Marker Lesion Experiments in Bladder Cancer—What Have We Learned?Journal of Urology, VOL. 183, NO. 5, (1678-1685), Online publication date: 1-May-2010.Hall M, Chang S, Dalbagni G, Pruthi R, Seigne J, Skinner E, Wolf J and Schellhammer P (2018) Guideline for the Management of Nonmuscle Invasive Bladder Cancer (Stages Ta, T1, and Tis): 2007 UpdateJournal of Urology, VOL. 178, NO. 6, (2314-2330), Online publication date: 1-Dec-2007.de REIJKE T, KURTH K, SYLVESTER R, HALL R, BRAUSI M, van de BEEK K, LANDSOGHT K and CARPENTIER P (2018) BACILLUS CALMETTE-GUERIN VERSUS EPIRUBICIN FOR PRIMARY, SECONDARY OR CONCURRENT CARCINOMA IN SITU OF THE BLADDER: RESULTS OF A EUROPEAN ORGANIZATION FOR THE RESEARCH AND TREATMENT OF CANCER—GENITO-URINARY GROUP PHASE III TRIAL (30906)Journal of Urology, VOL. 173, NO. 2, (405-409), Online publication date: 1-Feb-2005.Soloway M, Sofer M and Vaidya A (2018) Contemporary Management Of Stage T1 Transitional Cell Carcinoma Of The BladderJournal of Urology, VOL. 167, NO. 4, (1573-1583), Online publication date: 1-Apr-2002.Atan A and Basar M (2018) RE: INTRAVESICAL INTERLEUKIN-2 IN T1 PAPILLARY BLADDER CARCINOMA: REGRESSION OF MARKER LESION IN 8 OF 10 PATIENTSJournal of Urology, VOL. 162, NO. 5, (1706-1706), Online publication date: 1-Nov-1999.MASTERS J, POPERT R, THOMPSON P, GIBSON D, COPTCOAT M and PARMAR M (2018) INTRAVESICAL CHEMOTHERAPY WITH EPIRUBICIN: A DOSE RESPONSE STUDYJournal of Urology, VOL. 161, NO. 5, (1490-1493), Online publication date: 1-May-1999.Kurth K, Tunn U, Ay R, Schroder F, Pavone-Macaluso M, Debruyne F, Ten Kate F, De Pauw M and Sylvester R (2018) Adjuvant Chemotherapy for Superficial Transitional Cell Bladder Carcinoma: Long-term Results of a European Organization for Research and Treatment of Cancer Randomized Trial Comparing Doxorubicin, Ethoglucid and Transurethral Resection AloneJournal of Urology, VOL. 158, NO. 2, (378-384), Online publication date: 1-Aug-1997.Lamm D, Riggs D, Traynelis C and Nseyo U (2018) Apparent Failure of Current Intravesical Chemotherapy Prophylaxis to Influence the Long-Term Course of Superficial Transitional Cell Carcinoma of the BladderJournal of Urology, VOL. 153, NO. 5, (1444-1450), Online publication date: 1-May-1995.Glazier D, Bahnson R, McLeod D, von Roemeling R, Messing E and Ernstoff M (2018) Intravesical Recombinant Tumor Necrosis Factor in the Treatment of Superficial Bladder Cancer: An Eastern Cooperative Oncology Group StudyJournal of Urology, VOL. 154, NO. 1, (66-68), Online publication date: 1-Jul-1995.Hudson M and Herr H (2018) Carcinoma in Situ of the BladderJournal of Urology, VOL. 153, NO. 3, (564-572), Online publication date: 1-Mar-1995.Bouffioux C, Denis L, Oosterlinck W, Viggiano G, Vergison B, Keuppens F, De Pauw M, Sylvester R and Cheuvart B (2018) Adjuvant Chemotherapy of Recurrent Superficial Transitional Cell Carcinoma: Results of a European Organization for Research on Treatment of Cancer Randomized Trial Comparing Intravesical Instillation of Thiotepa, Doxorubicin and CisplatinJournal of Urology, VOL. 148, NO. 2 Part 1, (297-301), Online publication date: 1-Aug-1992.Tarkington M, Sommers C, Gelmann E, Tefft M and Lynch J (2018) The Effect of pH on the In Vitro Colony Forming Ability of Transitional Cell Carcinoma Cells Treated with Various Chemotherapeutic Agents: Implications for In Vivo TherapyJournal of Urology, VOL. 147, NO. 2, (511-513), Online publication date: 1-Feb-1992.Soloway M (2018) Editorial CommentsJournal of Urology, VOL. 143, NO. 4, (716-716), Online publication date: 1-Apr-1990.Hardeman S, Perry A and Soloway M (2018) Transitional Cell Carcinoma of the Prostate Following Intravesical Therapy for Transitional Cell Carcinoma of the BladderJournal of Urology, VOL. 140, NO. 2, (289-292), Online publication date: 1-Aug-1988.Heney N, Koontz W, Barton B, Soloway M, Trump D, Hazra T and Weinstein R (2018) Intravesical Thiotepa versus Mitomycin C in Patients with TA, T1 and TIS Transitional Cell Carcinoma of the Bladder: A Phase III Prospective Randomized StudyJournal of Urology, VOL. 140, NO. 6, (1390-1393), Online publication date: 1-Dec-1988.Herr H, Laudone V and Whitmore W (2018) An Overview of Intravesical Therapy for Superficial Bladder TumorsJournal of Urology, VOL. 138, NO. 6, (1363-1368), Online publication date: 1-Dec-1987.Soloway M and Perry A (2018) Bacillus Calmette-Guerin for Treatment of Superficial Transitional Cell Carcinoma of the Bladder in Patients who have failed Thiotepa and/or Mitomycin CJournal of Urology, VOL. 137, NO. 5, (871-873), Online publication date: 1-May-1987.Catalona W (2018) Editorial CommentJournal of Urology, VOL. 137, NO. 5, (873-873), Online publication date: 1-May-1987.Flanigan R, Ellison M, Butler K, Gomella L and McRoberts J (2018) A Trial of Prophylactic Thiotepa or Mitomycin C Intravesical Therapy in Patients with Recurrent or Multiple Superficial Bladder CancersJournal of Urology, VOL. 136, NO. 1 Part 1, (35-37), Online publication date: 1-Jul-1986.Pode D, Alon Y, Horowitz A, Vlodavsky I and Biran S (2018) The Mechanism of Human Bladder Tumor Implantation in an in Vitro ModelJournal of Urology, VOL. 136, NO. 2, (482-486), Online publication date: 1-Aug-1986.Schellhammer P, Ladaga L and Fillion M (2018) Bacillus Calmette-Guerin for Superficial Transitional Cell Carcinoma of the BladderJournal of Urology, VOL. 135, NO. 2, (261-264), Online publication date: 1-Feb-1986.Droller M and Erozan Y (2018) Thiotepa Effects on Urinary Cytology in the Interpretation of Transitional Cell CancerJournal of Urology, VOL. 134, NO. 4, (671-674), Online publication date: 1-Oct-1985.Droller M and Walsh P (2018) Intensive Intravesical Cheiviotherapy in the Treatment of Flat Carcinoma in Situ: Is it Safe?Journal of Urology, VOL. 134, NO. 6, (1115-1117), Online publication date: 1-Dec-1985.Green D, Robinson M, Glashan R, Newling D, Dalesio O and Smith P (2018) Does Intravesical Chemotherapy Prevent Invasive Bladder Cancer?Journal of Urology, VOL. 131, NO. 1, (33-35), Online publication date: 1-Jan-1984.Soloway M (2018) Editorial CommentJournal of Urology, VOL. 131, NO. 1, (35-35), Online publication date: 1-Jan-1984. (2018) Reply by AuthorsJournal of Urology, VOL. 131, NO. 1, (46-46), Online publication date: 1-Jan-1984.Soloway M and Ford K (2018) Subsequent Tumor Analysis of 36 Patients Who Have Received Intravesical Mitomycin C for Superficial Bladder CancerJournal of Urology, VOL. 130, NO. 1, (74-77), Online publication date: 1-Jul-1983.Droller M (2018) Editorial CommentJournal of Urology, VOL. 130, NO. 1, (77-78), Online publication date: 1-Jul-1983.Prout G, Koontz W, Coombs L, Hawkins I and Friedell G (2018) Long-term Fate of 90 Patients with Superficial Bladder Cancer Randomly Assigned to Receive or not to Receive ThiotepaJournal of Urology, VOL. 130, NO. 4, (677-680), Online publication date: 1-Oct-1983.Soloway M and Ford K (2018) Thiotepa-induced Myelosuppression: Review of 670 Bladder InstillationsJournal of Urology, VOL. 130, NO. 5, (889-891), Online publication date: 1-Nov-1983.Heney N, Ahmed S, Flanagan M, Frable W, Corder M, Hafermann M and Hawkins I (2018) Superficial Bladder Cancer: Progression and RecurrenceJournal of Urology, VOL. 130, NO. 6, (1083-1086), Online publication date: 1-Dec-1983.Utz D (2018) Editorial CommentsJournal of Urology, VOL. 130, NO. 6, (1086-1086), Online publication date: 1-Dec-1983.Droller M (2018) Editorial CommentsJournal of Urology, VOL. 130, NO. 6, (1086-1086), Online publication date: 1-Dec-1983.Lundbeck F, Mogensen P and Jeppesen N (2018) Intravesical Therapy of Noninvasive Bladder Tumors (Stage Ta) with Doxorubicin and UrokinaseJournal of Urology, VOL. 130, NO. 6, (1087-1089), Online publication date: 1-Dec-1983. (2018) Reply by AuthorJournal of Urology, VOL. 129, NO. 1, (32-32), Online publication date: 1-Jan-1983.Prout G (2018) Bladder CancerJournal of Urology, VOL. 128, NO. 2, (284-284), Online publication date: 1-Aug-1982.Whitmore W and Prout G (2018) Discouraging Results for High Dose External Beam Radiation Therapy in Low Stage (O and A) Bladder CancerJournal of Urology, VOL. 127, NO. 5, (902-905), Online publication date: 1-May-1982.Radwin H (2018) Editorial CommentJournal of Urology, VOL. 127, NO. 5, (905-905), Online publication date: 1-May-1982.Prout G, Griffin P, Nocks B, DeFuria M and Daly J (2018) Intravesical Therapy of Low Stage Bladder Carcinoma with Mitomycin C: Comparison of Results in Untreated and Previously Treated PatientsJournal of Urology, VOL. 127, NO. 6, (1096-1098), Online publication date: 1-Jun-1982.Soloway M (2018) Editorial CommentJournal of Urology, VOL. 127, NO. 6, (1098-1098), Online publication date: 1-Jun-1982. (2018) Reply by AuthorsJournal of Urology, VOL. 127, NO. 6, (1098-1098), Online publication date: 1-Jun-1982. Volume 125Issue 3March 1981Page: 307-312 Advertisement Copyright & Permissions© 1981 by The American Urological Association Education and Research, Inc.MetricsAuthor Information Warren W. Koontz More articles by this author George R. Prout More articles by this author Wade Smith More articles by this author William J. Frable More articles by this author Janet E. Minnis More articles by this author Expand All Advertisement PDF downloadLoading ...
No takes yet. Share an insight, caveat, or question.
Koontz et al. (1981) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: